<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02664753</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-N/2015/PR-01</org_study_id>
    <nct_id>NCT02664753</nct_id>
  </id_info>
  <brief_title>L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury</brief_title>
  <acronym>CarniSave</acronym>
  <official_title>L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare 28 day mortality rates between septic shock
      patients with acute renal insufficiency treated via L-Carnitine (as an adjunct therapy)
      versus a similar group of patients not receiving L-Carnitine adjunct therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are:

      A. First secondary objective of this study is to compare 10 day mortality rates of septic
      shock patients with renal insufficiency treated via L-Carnitine (as an adjunct therapy) for
      56 days versus a patients not receiving L-Carnitine adjunct therapy

      B. To compare study arms in terms of patient safety.

      C. To compare study arms in terms of further clinical outcomes, with special emphasis on
      nephrological outcomes.

      D. To study (and compare between arms) the kinetic curves of free and total serum carnitine.
      Renal replacement therapy rapidly depletes the body's carnitine levels. Tracking adequate
      carnitine levels is therefore important for the interpretation of study results.

      E. To constitute a bio-bank in association with the study for future ancillary studies (e.g.
      kidney injury marker studies, carnitine-responders versus non-responders, and other
      exploratory studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>First secondary objective of this study is to compare 10 day mortality rates of septic shock patients with renal insufficiency treated via L-Carnitine (as an adjunct therapy) for 56 days versus a patients not receiving L-Carnitine adjunct therapy.</measure>
    <time_frame>10 days</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events per patient</measure>
    <time_frame>12 months (throughout study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>12 months (throughout study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days alive and not on renal replacement therapy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days alive and free of renal failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days alive and free of organ failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days alive and not on mechanical ventilation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days alive and not in Intensive Care Unit (ICU)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days alive and not in hospital</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days alive and free of (not requiring) catecholamines</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A vector of repeated measures of daily SOFA (Sequential Organ Failure Assessment score) scores available during the ICU stay</measure>
    <time_frame>at ICU discharge (expected max of 28 days)</time_frame>
    <description>Available daily scores will be aggregated into a vector for repeated measures analysis (similar to the agregation required for calculating a slope).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A vector of repeated measures of AKIN (Acute Kidney Injury Network score) score available during the ICU stay</measure>
    <time_frame>at ICU discharge (expected max of 28 days)</time_frame>
    <description>Available daily scores will be aggregated into a vector for repeated measures analysis (similar to the agregation required for calculating a slope).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A vector of repeated measures of serum creatinine</measure>
    <time_frame>at ICU discharge (expected max of 28 days)</time_frame>
    <description>Available measures will be aggregated into a vector for repeated measures analysis (similar to the agregation required for calculating a slope).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A vector of repeated measures of serum creatinine</measure>
    <time_frame>at discharge from the nephrology department (expected max of 60 days)</time_frame>
    <description>Available measures will be aggregated into a vector for repeated measures analysis (similar to the agregation required for calculating a slope).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A vector of repeated measures of lactate levels available during the ICU stay</measure>
    <time_frame>at ICU discharge (expected max of 28 days)</time_frame>
    <description>Available measures will be aggregated into a vector for repeated measures analysis (similar to the agregation required for calculating a slope).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (EpiCKD)</measure>
    <time_frame>month 1</time_frame>
    <description>(if the patient is on dialysis, the glomerular filtration rate is set at 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (EpiCKD)</measure>
    <time_frame>month 2</time_frame>
    <description>(if the patient is on dialysis, the glomerular filtration rate is set at 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (EpiCKD)</measure>
    <time_frame>month 3</time_frame>
    <description>(if the patient is on dialysis, the glomerular filtration rate is set at 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (EpiCKD)</measure>
    <time_frame>month 6</time_frame>
    <description>(if the patient is on dialysis, the glomerular filtration rate is set at 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (EpiCKD)</measure>
    <time_frame>month 9</time_frame>
    <description>(if the patient is on dialysis, the glomerular filtration rate is set at 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (EpiCKD)</measure>
    <time_frame>month 12</time_frame>
    <description>(if the patient is on dialysis, the glomerular filtration rate is set at 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free carnitine level</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free carnitine level</measure>
    <time_frame>after 48h of renal replacement therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free carnitine level</measure>
    <time_frame>day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free carnitine level</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free carnitine level</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free carnitine level</measure>
    <time_frame>month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total carnitine level</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total carnitine level</measure>
    <time_frame>after 48h of renal replacement therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total carnitine level</measure>
    <time_frame>day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total carnitine level</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total carnitine level</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total carnitine level</measure>
    <time_frame>month 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Shock, Septic</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>L-Carnitine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.
Intervention: 56 days of weight-adjusted L-Carnitine treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then open group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).
Intervention: 10 days of intravenous placebo (isotonic saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>56 days of weight-adjusted L-Carnitine treatment</intervention_name>
    <description>Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.
Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.
Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes
For the next 46 days, patients will take oral doses of L-Carnitine as follows:
&lt; à 60kg : 2g/day &gt; 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization</description>
    <arm_group_label>L-Carnitine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 days of intravenous placebo (isotonic saline)</intervention_name>
    <description>Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).
Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening.</description>
    <arm_group_label>Placebo then open group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The emergency inclusion procedure was correctly applied according to French law
             (signature of consent form by a patient-designated trusted person or a family member,
             or a medical decision to proceed with patient inclusion if the latter two persons are
             unavailable) ---- OR ---- signature of the consent form by the patient

          -  The patient must be insured or beneficiary of a health insurance plan

          -  The patient is at least 18 years old

          -  The patient has been admitted to a participating ICU for severe sepsis or septic shock
             within the last 72 hours

          -  The patient has sepsis or septic shock according to international criteria SEPSIS 3
             (Singer et al, The Third International Consensus Definitions for Sepsis and Septic
             Shock (Sepsis-3) ; JAMA. 2016)

          -  • The patient has acute renal insufficiency with an KDIGO score of 3

          -  The patient has started continuous renal replacement therapy (CRRT) or intermittent
             renal replacement therapy (IRRT) within the past 24 hours, or will start RRT (CRRT or
             IRRT) within the next 24 hours

        Exclusion Criteria:

          -  The patient is participating in, or has participated in over the past three months,
             another interventional study that may interfere with the results or conclusions of
             this study

          -  The patient is in an exclusion period determined by a previous study

          -  The patient is under judicial protection, or is an adult under guardianship

          -  If the patient is unable to sign a consent form: the patient-designated trusted person
             or family member refuses to sign the consent form

          -  If the patient is unable to sign a consent form: It is impossible to correctly inform
             the patient-designated trusted person or family member

          -  The patient is able/apt to sign a consent form, but refuses to do so

          -  The patient is able/apt to sign a consent form, but cannot be correctly informed

          -  Septic shock without associated AKI

          -  Patients with a known allergy to L-Carnitine

          -  Pre-existing chronic disease requiring dialysis

             • The patient has stage 4 CKD with baseline DFG (CDK) if known &lt;30 ml

          -  History of seizures or epilepsy

          -  Chronic bowel disease or history of chronic diarrhoea

          -  Under treatment with sodium valproate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Reboul, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal Reboul, MD</last_name>
    <phone>+33.(0)4.66.68.35.56</phone>
    <email>pascal.reboul@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen Cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thierry Lobbedez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien Ducheyron, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Chartres</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Kalfon</last_name>
    </contact>
    <investigator>
      <last_name>pierre kalfon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bertrand Souweine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Elizabeth Heng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Pierre Quenot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Michel Rebibou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital Nord</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc Leone, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stéphane Burtey, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion SALLEE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital de la Timone Adultes</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nicolas Bruder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - St Eloi</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Samir Jaber, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kada Klouche, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Jonquet, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georges Mourad, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Muller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saber Barbar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves Lefrant, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Moranne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Lumbroso, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David-Paul de Brauwère, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>claire DAHYOT-FIZELIER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Bridoux, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>thibaut papet</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>marc bauwens</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de St Etienne</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric Alamartine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Mariat, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059 T</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominique Chauveau, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Cointault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>nassim kamar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>stanislas faguer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003 Apr;31(4):1250-6. Review.</citation>
    <PMID>12682500</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

